NCT02512926
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Misc Inhibitor, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 6 Months to 29 Years (Child, Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Central nervous system (CNS) metastases
https://ClinicalTrials.gov/show/NCT02512926